BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zenyaku Kogyo readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Zenyaku Kogyo's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03758989-4915@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03758989)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of PET Adapted Therapy and Non-invasive Monitoring for Pre
 viously Untreated Limited Stage Diffuse Large B Cell Lymphoma\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03758989
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04594798-4915@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04594798)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Polatuzumab V
 edotin\, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL\nE
 stimated primary completion: 31 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04594798
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-4915@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06047080)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: An Open-Label Study Comp
 aring Glofitamab and Polatuzumab Vedotin + Rituximab\, Cyclophosphamide\, 
 Doxorubicin\, and Prednisone Versus Pola-R-CHP in Previously Untreated Pat
 ients With Large B-Cell Lymphoma\nEstimated primary completion: 1 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047080
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-4915@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study to Evaluate Gl
 ofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and 
 Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgki
 n Lymphoma\nEstimated primary completion: 30 November 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
